Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer
Abstract Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to c...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-09-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13582 |
| _version_ | 1818967436553093120 |
|---|---|
| author | Yuriko Ueki Manabu Suzuki Yuriko Horikawa Hiromu Watanabe Yoh Yamaguchi Chie Morita Akinari Tsukada Hiroshi Takumida Yusaku Kusaba Takashi Katsuno Yoshie Tsujimoto Keita Sakamoto Masao Hashimoto Junko Terada Satoru Ishii Jin Takasaki Go Naka Motoyasu Iikura Shinyu Izumi Yuichiro Takeda Masayuki Hojo Haruhito Sugiyama |
| author_facet | Yuriko Ueki Manabu Suzuki Yuriko Horikawa Hiromu Watanabe Yoh Yamaguchi Chie Morita Akinari Tsukada Hiroshi Takumida Yusaku Kusaba Takashi Katsuno Yoshie Tsujimoto Keita Sakamoto Masao Hashimoto Junko Terada Satoru Ishii Jin Takasaki Go Naka Motoyasu Iikura Shinyu Izumi Yuichiro Takeda Masayuki Hojo Haruhito Sugiyama |
| author_sort | Yuriko Ueki |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to control most cases of myelosuppression. Here, we report an 88‐year‐old woman with squamous cell lung cancer who was administered pembrolizumab. After five cycles of pembrolizumab, she developed severe pancytopenia. The pancytopenia improved under observation without steroid administration after cessation of pembrolizumab. During recovery from this irAE, the patient also maintained long‐term antitumor efficacy. Key points Significant findings of the study There are several kinds of immune‐related adverse events. We encountered a case of pembrolizumab‐induced pancytopenia with squamous cell lung cancer. What this study adds Corticosteroids are needed to control most cases of myelosuppression induced by ICIs, but pancytopenia induced by pembrolizumab in our case improved without steroids. |
| first_indexed | 2024-12-20T13:48:46Z |
| format | Article |
| id | doaj.art-25dedb817d3148c69a374d619a8d248d |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-20T13:48:46Z |
| publishDate | 2020-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-25dedb817d3148c69a374d619a8d248d2022-12-21T19:38:34ZengWileyThoracic Cancer1759-77061759-77142020-09-011192731273510.1111/1759-7714.13582Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancerYuriko Ueki0Manabu Suzuki1Yuriko Horikawa2Hiromu Watanabe3Yoh Yamaguchi4Chie Morita5Akinari Tsukada6Hiroshi Takumida7Yusaku Kusaba8Takashi Katsuno9Yoshie Tsujimoto10Keita Sakamoto11Masao Hashimoto12Junko Terada13Satoru Ishii14Jin Takasaki15Go Naka16Motoyasu Iikura17Shinyu Izumi18Yuichiro Takeda19Masayuki Hojo20Haruhito Sugiyama21Department of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanDepartment of Respiratory Medicine National Centre for Global Health and Medicine Shinjuku‐ku JapanAbstract Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to control most cases of myelosuppression. Here, we report an 88‐year‐old woman with squamous cell lung cancer who was administered pembrolizumab. After five cycles of pembrolizumab, she developed severe pancytopenia. The pancytopenia improved under observation without steroid administration after cessation of pembrolizumab. During recovery from this irAE, the patient also maintained long‐term antitumor efficacy. Key points Significant findings of the study There are several kinds of immune‐related adverse events. We encountered a case of pembrolizumab‐induced pancytopenia with squamous cell lung cancer. What this study adds Corticosteroids are needed to control most cases of myelosuppression induced by ICIs, but pancytopenia induced by pembrolizumab in our case improved without steroids.https://doi.org/10.1111/1759-7714.13582Immune checkpoint inhibitorimmune‐related adverse event (irAE)pancytopeniaPD‐L1squamous cell lung cancer |
| spellingShingle | Yuriko Ueki Manabu Suzuki Yuriko Horikawa Hiromu Watanabe Yoh Yamaguchi Chie Morita Akinari Tsukada Hiroshi Takumida Yusaku Kusaba Takashi Katsuno Yoshie Tsujimoto Keita Sakamoto Masao Hashimoto Junko Terada Satoru Ishii Jin Takasaki Go Naka Motoyasu Iikura Shinyu Izumi Yuichiro Takeda Masayuki Hojo Haruhito Sugiyama Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer Thoracic Cancer Immune checkpoint inhibitor immune‐related adverse event (irAE) pancytopenia PD‐L1 squamous cell lung cancer |
| title | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
| title_full | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
| title_fullStr | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
| title_full_unstemmed | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
| title_short | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
| title_sort | pembrolizumab induced pancytopenia in a patient with squamous cell lung cancer |
| topic | Immune checkpoint inhibitor immune‐related adverse event (irAE) pancytopenia PD‐L1 squamous cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.13582 |
| work_keys_str_mv | AT yurikoueki pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT manabusuzuki pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT yurikohorikawa pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT hiromuwatanabe pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT yohyamaguchi pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT chiemorita pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT akinaritsukada pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT hiroshitakumida pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT yusakukusaba pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT takashikatsuno pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT yoshietsujimoto pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT keitasakamoto pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT masaohashimoto pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT junkoterada pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT satoruishii pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT jintakasaki pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT gonaka pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT motoyasuiikura pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT shinyuizumi pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT yuichirotakeda pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT masayukihojo pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT haruhitosugiyama pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer |